The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.
 
Paolo Tarantino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Gilead Sciences; Lilly; Novartis
Research Funding - AstraZeneca
 
Tianyu Li
No Relationships to Disclose
 
Clare Strickland
No Relationships to Disclose
 
Michelle DeMeo
No Relationships to Disclose
 
Leilani Anderson
No Relationships to Disclose
 
Esther Pasternak
No Relationships to Disclose
 
Carey Anders
Honoraria - AstraZeneca; Athenex; Beigene; Elucida Oncology; Genentech/Roche; Immunomedics; Novartis; Seagen
Consulting or Advisory Role - AstraZeneca; Athenex; Beigene; Eisai; Elucida Oncology; Genentech/Roche; Immunomedics; Roche; Seagen
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Caris Life Sciences (Inst); Elucida Oncology (Inst); G1 Therapeutics (Inst); Incyclix Bio (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; Up to Date.com
Travel, Accommodations, Expenses - Eisai
 
Manmeet Ahluwalia
Stock and Other Ownership Interests - doctible; MedInnovate Advisors LLC; MimiVax; TriSalus Life Sciences
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - AlloVir; Anheart Therapeutics; Apollomics; Autem Therapeutics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; Equillium; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; Siemens Healhineers/Varian Medical Systems; Sumitomo Dainippon Pharma Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
Reshma Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
 
Liangge Hsu
No Relationships to Disclose
 
Sarah Ossing
Employment - Dana-Farber Cancer Institute
 
Nabihah Tayob
No Relationships to Disclose
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Nancy Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - AstraZeneca; Olema Pharmaceuticals
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Incyclix Bio; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)